Annual EBITDA
-$216.24 M
-$73.03 M-51.00%
December 31, 2024
Summary
- As of March 10, 2025, KYMR annual EBITDA is -$216.24 million, with the most recent change of -$73.03 million (-51.00%) on December 31, 2024.
- During the last 3 years, KYMR annual EBITDA has fallen by -$118.59 million (-121.45%).
- KYMR annual EBITDA is now -917.77% below its all-time high of -$21.25 million, reached on December 31, 2018.
Performance
KYMR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$68.71 M
-$8.27 M-13.68%
December 31, 2024
Summary
- As of March 10, 2025, KYMR quarterly EBITDA is -$68.71 million, with the most recent change of -$8.27 million (-13.68%) on December 31, 2024.
- Over the past year, KYMR quarterly EBITDA has dropped by -$55.28 million (-411.78%).
- KYMR quarterly EBITDA is now -820.01% below its all-time high of -$7.47 million, reached on September 30, 2020.
Performance
KYMR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$216.24 M
-$55.28 M-34.35%
December 31, 2024
Summary
- As of March 10, 2025, KYMR TTM EBITDA is -$216.24 million, with the most recent change of -$55.28 million (-34.35%) on December 31, 2024.
- Over the past year, KYMR TTM EBITDA has dropped by -$73.03 million (-51.00%).
- KYMR TTM EBITDA is now -1820.73% below its all-time high of -$11.26 million, reached on September 30, 2019.
Performance
KYMR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
KYMR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -51.0% | -411.8% | -51.0% |
| 3 y3 years | -121.5% | -411.8% | -51.0% |
| 5 y5 years | -435.6% | -411.8% | -51.0% |
KYMR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -121.5% | at low | -411.8% | at low | -121.5% | at low |
| 5 y | 5-year | -435.6% | at low | -820.0% | at low | -866.2% | at low |
| alltime | all time | -917.8% | at low | -820.0% | at low | -1820.7% | at low |
Kymera Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$216.24 M(+51.0%) | -$68.71 M(+13.7%) | -$216.24 M(+34.3%) |
| Sep 2024 | - | -$60.44 M(+50.9%) | -$160.96 M(+5.6%) |
| Jun 2024 | - | -$40.06 M(-14.8%) | -$152.45 M(+1.5%) |
| Mar 2024 | - | -$47.03 M(+250.3%) | -$150.23 M(+4.9%) |
| Dec 2023 | -$143.20 M(-5.6%) | -$13.43 M(-74.1%) | -$143.20 M(-12.6%) |
| Sep 2023 | - | -$51.93 M(+37.2%) | -$163.76 M(+6.3%) |
| Jun 2023 | - | -$37.85 M(-5.4%) | -$154.03 M(-1.1%) |
| Mar 2023 | - | -$39.99 M(+17.7%) | -$155.69 M(+2.7%) |
| Dec 2022 | -$151.66 M | -$33.99 M(-19.5%) | -$151.65 M(+0.5%) |
| Sep 2022 | - | -$42.20 M(+6.8%) | -$150.83 M(+10.5%) |
| Jun 2022 | - | -$39.51 M(+9.9%) | -$136.47 M(+12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$35.96 M(+8.4%) | -$121.04 M(+24.0%) |
| Dec 2021 | -$97.64 M(+123.4%) | -$33.16 M(+19.1%) | -$97.65 M(+27.4%) |
| Sep 2021 | - | -$27.84 M(+15.6%) | -$76.65 M(+36.2%) |
| Jun 2021 | - | -$24.08 M(+91.6%) | -$56.27 M(+23.0%) |
| Mar 2021 | - | -$12.57 M(+3.3%) | -$45.77 M(+4.7%) |
| Dec 2020 | -$43.72 M(+8.3%) | -$12.16 M(+62.8%) | -$43.72 M(+2.4%) |
| Sep 2020 | - | -$7.47 M(-45.0%) | -$42.68 M(-8.2%) |
| Jun 2020 | - | -$13.57 M(+29.2%) | -$46.47 M(+41.3%) |
| Mar 2020 | - | -$10.51 M(-5.5%) | -$32.89 M(+47.0%) |
| Dec 2019 | -$40.38 M(+90.0%) | -$11.12 M(-1.2%) | -$22.38 M(+98.8%) |
| Sep 2019 | - | -$11.26 M | -$11.26 M |
| Dec 2018 | -$21.25 M | - | - |
FAQ
- What is Kymera Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics annual EBITDA year-on-year change?
- What is Kymera Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly EBITDA year-on-year change?
- What is Kymera Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics TTM EBITDA year-on-year change?
What is Kymera Therapeutics annual EBITDA?
The current annual EBITDA of KYMR is -$216.24 M
What is the all time high annual EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high annual EBITDA is -$21.25 M
What is Kymera Therapeutics annual EBITDA year-on-year change?
Over the past year, KYMR annual EBITDA has changed by -$73.03 M (-51.00%)
What is Kymera Therapeutics quarterly EBITDA?
The current quarterly EBITDA of KYMR is -$68.71 M
What is the all time high quarterly EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly EBITDA is -$7.47 M
What is Kymera Therapeutics quarterly EBITDA year-on-year change?
Over the past year, KYMR quarterly EBITDA has changed by -$55.28 M (-411.78%)
What is Kymera Therapeutics TTM EBITDA?
The current TTM EBITDA of KYMR is -$216.24 M
What is the all time high TTM EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high TTM EBITDA is -$11.26 M
What is Kymera Therapeutics TTM EBITDA year-on-year change?
Over the past year, KYMR TTM EBITDA has changed by -$73.03 M (-51.00%)